[Retracted] Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer

Table 4

Multivariate logistic regression analysis of ORR.

Variables	OR	95% CI
Age (>50 years old vs. ≤50 years old)	1.063	0.859~1.303	0.296
Comorbidities (yes vs. no)	1.380	1.027~1.664	0.020
Surgery (yes vs. no)	0.905	0.695~0.980	0.032
Pathological type (invasive cancer vs. other)	1.125	0.730~1.308	0.296